The clinical effects of the oral beta, partial agonist, prenalterol, were investigated in 37 patients (29 male, eight female; mean age 57 years) with chronic ischaemic left ventricular failure using a placebo controlled randomised double blind protocol over six months. All patients were limited by dyspnoea (New York Heart Association class III) despite treatment with digoxin and diuretics. Twenty eight patients completed the protocol. Moderate clinical improvement was seen in the prenalterol group, whereas there was little change in the placebo group. Bicycle exercise capacity increased over six months in the prenalterol and placebo groups but only achieved statistical significance for prenalterol when compared with baseline values. Maximum exercise heart rate was significantly reduced in the prenalterol group compared with placebo. Radionuclide left ventricular ejection fraction at rest and during exercise and cardiothoracic ratio showed nosignificant improvement in either group over six months. Prenalterol was well tolerated and produced no increase in frequency of angina or ventricular arrhythmias.
The management of patients with chronic ischaemic left ventricular failure is often difficult and unsatisfactory and usually requires multiple drug treatment. 1 The prognosis is poor despite treatment.2 The conventional management is with diuretics and cardiac glycosides,l and, although the role of cardiac glycosides remains controversial,34 recent studies have confirmed that some inotropic support is maintained in patients in sinus rhythm,5-7 especially those with an audible third heart sound.8 In the past decade there has been increasing interest in both vasodilator
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The role of beta agonists in the management of heart failure has recently been reviewed.1213 The beta2 agonists salbutamol and pirbuterol produce beneficial effects mainly by vasodilatation.14 At present, there are apparently only two orally active selective beta1 partial agonists: prenalterol and xamoterol [Corwin] (maximum agonist activity is 8O0/o15 and 43%16 of that of isoprenaline respectively). Both drugs exert a positive inotropic effect acutely'6 17 and during short term maintenance treatment. '8 19 There is, however, a need for long term placebo controlled studies of these drugs in the management of left ventricular failure.'3 The occurrence of side effect in animals has led to the withdrawal of prenalterol, but our studies may be of more general interest. 208 No statistically significant differences prenalterol vs placebo.
In this study the clinical effects of the beta, partial agonist prenalterol were assessed using a placebo controlled double blind protocol of six months' duration in patients with stable chronic ischaemic left ventricular failure.
Patients and methods

STUDY POPULATION
Patients were recruited during routine outpatient practice at three centres (Birmingham, Edinburgh, and Cambridge). A total of 37 patients entered the study (29 men, eight women), aged from 41 to 70 years (mean (SD) 57(7) years). All the patients were selected on the basis of having chronic left ventricular failure (duration >3 months) secondary to ischaemic heart disease and exercise tolerance limited by dyspnoea (New York Heart Association functional class III) despite treatment with digoxin and diuretics.
Patients were excluded from the study if they had sustained a myocardial infarction within the previous three months, had valvar heart disease, or obstructive airways disease. Glover, Wathen, Murray, Petch, Muir, Litler at 20 W for two minutes and subsequently increased by 10 W per minute. The patient's heart rate and rhythm were continuously monitored and the heart rate and systolic blood pressure recorded at the end of each workload. Blood pressure was measured using a standard mercury sphygmomanometer.
Radionuclide angiography-Radionuclide angiography was performed following in vivo red cell labelling with 740 MBq technetium 99 m. Image data were aquired using a mobile gammacamera in the anterior and left anterior oblique projections at rest and the left anterior oblique projection during supine dynamic exercise. Count dependent global left ventricular ejection fraction was calculated from the background corrected time-activity curves from resting and exercise left anterior oblique images. Exercise was performed supine using an electrically braked bicycle ergometer. A single step protocol was used with a work level approximately 50% of the erect maximal level previously determined. A total of four minutes supine exercise was performed with image data acquisition during the last three minutes.
Chest radiography-A standard posteroantenor chest x ray film was taken at six feet for determination of the cardiothoracic ratio.
Ambulatory electrocardiographic monitoringStandard 24 No statistically significant differences prenalterol vs placebo.
matched at entry with no significant differences between the treatment groups (Table 1) . The optimal doses of prenalterol determined by dose titration were as follows: 100 mg twice daily, 17 patients (16 male, one female); 50 mg twice daily, 15 patients (nine male, six female); and 20 mg twice daily, 5 patients (four male, one female).
DEATHS, WITHDRAWALS, AND PROTOCOL VIOLATIONS
Two patients in each group died during the study, and two patients taking prenalterol and three placebo were withdrawn from the study ( Table 2 ). During the study period the dose of diuretic (frusemide) had to be increased in two patients, from 80 mg to 160 mg/day in one case and from 80 mg to 240 mg/day in the other, because of deteriorating heart failure. Both patients were in the placebo group. [151 124 [151 123 (14-7) [14] Placebo 117 (13-0) [15] 118 (14-4) [15] 115 (17-1) [13] 115 [13] 2-9 (0-76) [13] Radionuclide ejection fraction at rest [10] 83 [91 80 (8- [12] 112 Table 3 shows resting heart rate and blood pressures. There were no significant differences between the groups before or during the study.
CLINICAL SCORES AND NYHA CLASSIFICATION Figure 2 summarises the clinical scores. In the prenalterol group the increase in clinical scores corresponds to moderate improvement at three and six months. Fourteen of the 19 patients showed a positive clinical response with an increased score. In the placebo group the increase in clinical score corresponds to slight improvement, with 10 of the 18 patients having a small increase in score. The standard deviations (SD) for this group were large in contrast to the prenalterol group, which is a reflection of the variability in clinical response in the placebo group. Statistical significance (Wilcoxon test) was not reached for the differences in cumulative clinical score between the prenalterol and placebo groups.
The NYHA classification (Table 3) showed a trend in favour of the prenalterol group which was not statistically significant. Figure 3 shows the results.
Maximum heart rate was significantly reduced in the prenalterol group at one month (p<0001), three months (p<005), and six months (p<0-01) compared with placebo. On drug withdrawal there was a return to control values.
During the control period systolic blood pressure at the end of exercise was significantly higher in the prenalterol group than in the placebo group (p<00S). There was a tendency for the systolic blood pressure to be reduced in the prenalterol group during the treatment period, and this change reached statistical significance compared with placebo after one month (p<0-05). There was little change in the placebo values.
Rate pressure products were calculated from the above data and were found to be significantly reduced in the prenalterol group at one month (p<0.001), three months (p<005), and six months (p<001) compared with placebo.
The mimum workload (watts) achieved by the prenalterol group was significantly increased at one month (p<005) and six months (p<001) compared with control values. There was a significant increase in' the placebo group at one month (p<005), but there were no significant differences between the treatment groups. On drug withdrawal there was no significant change in maximum workload achieved in either group.
The total work performed (watts mins) by the prenalterol group was significantly increased at one month (p<0-05) and at six months (p<0-01) compared with control values. In the placebo group there was a significant improvement at one month (p<0-05) compared with control values, but this was not maintained. There were, however, no significant differences between the groups.
RADIONUCLIDE ANGIOGRAPHY AND CHEST RADIOGRAPHY
Seven of the patients were in atrial fibrillation and were not studied. Table 3 shows the radionuclide left ventricular ejection fractions at rest and during exercise. There were no significant changes in the resting or exercise ejection fractions within the treatment groups during the study. Nevertheless, the differences between the groups for resting values alone at one month achieved statistical significance (p<005). The heart rate during supine exercise was significantly reduced in the prenalterol group compared with placebo at one and three months (p<005) ( Table 3) .
There was little change (NS) in the cardiothoracic ratio in both groups during the study (Table 3) .
AMBULATORY ELECTROCARDIOGRAPHIC MONITORING
Cardiac arrhythmias were often recorded in the absence of symptoms in both groups at entry and during the trial period. Nevertheless, there was no significant difference in the occurrence of ventricular arrhythmias (Lown score) during the trial between the treatment groups (Table 3) .
HAEMATOLOGICAL AND BIOCHEMICAL ANALYSES
No significant changes were observed in any of the standard haematological or biochemical analyses during the study period. In particular, there were no changes in serum glucose, potassium, or creatinine concentrations. Plasma digoxin and prenalterol concentrations confirmed drug compliance in all patients (Table 3) .
UNWANTED EFFECTS Table 4 shows the unwanted effects reported by patients. There was little difference in the incidence of unwanted effects between the groups. Four patients in each treatment group had the dose of study drug reduced because of unwanted effects. Digoxin was reduced in one patient in the placebo group and isosorbide dinitrate in one patient on prenalterol with good effect. No statistically significant differences prenalterol vs placebo.
Discussion
In this study long term oral prenalterol treatment has been shown to be clinically beneficial, tending to improve symptoms and exercise tolerance in patients with chronic ischaemic left ventricular failure. These 214 benefits appear to have occurred in the absence of any detectable improvement in left ventricular performance and were associated with a heart rate sparing effect during exercise. We also noted pronounced placebo response. The selective beta1 agonist, prenalterol, has been shown to have a significant positive inotropic effect when given intravenously,22-25 and recently the inotropic effect has been confirmed during an acute oral dose-response study,17 and during a short term oral double blind crossover study against placebo.'8 These changes have occurred in the absence of alterations in left ventricular preload and afterload. The improvement in exercise capacity which we found provides some indirect evidence of a positive inotropic effect, which was not detected by radionuclide angiography. Small changes in left ventricular ejection fraction are difficult to detect in patients with dilated poorly contracting hearts but could be of clinical importance. The lack of correlation between exercise capacity and left ventricular ejection fraction has been well documented in patients with left ventricular failure,2627 and compensatory mechanisms have been suggested to explain this. 28 Chronic treatment with beta agonists could possibly produce tachyphylaxis owing to activation of the renin-angiotensin system29 and "down regulation" of beta receptors. 30 It is interesting that we did not observe such tachyphylaxis. There was a small but insignificant weight gain in the prenalterol group. Nevertheless, none of these patients developed oedema or other symptoms of fluid retention, and we have attributed this increase in weight gain to the improved appetite and general well being observed during prenalterol treatment. Another possible disadvantage of beta stimulation is induction of cardiac arrhythmias and angina. We found no evidence that ventricular arrhythmias increased in the prenalterol group, and only two patients were withdrawn from the study because of increasing angina; both were taking placebo.
The attenuation in heart rate on maximal and submaximal exercise could have been the main way in which benefit was produced.3' This attenuation was similar to that observed with conventional beta blocker treatment, even in patients with cardiac failure.32 This leads us to propose that prenalterol reduces exercise heart rate by partial beta blockade. Consequently, the theoretical disadvantage of a full beta agonist-namely, increased myocardial oxygen demand-would be prevented. Indeed analysis of the rate-pressure product which approximates to myocardial oxygen consumption33 is in keeping with this view. It may also explain our observation that the incidence of angina was not increased and that few arrhythmias were encountered. The finding that preGlover, Wathen, Murray, Petchl, Muir, Littler nalterol did not depress left ventricular performance supports the fact that it is not a full beta blocker. 32 The observed clinical improvement in 10 patients in the placebo group warrants further comment. This was perhaps due to the extra interest shown in the patients. They were severely limited by symptoms despite maximal conventional treatment and consequently were grateful for any hope offered by trial treatment. Compliance in such patients is usually excellent and was confirmed in this study.
Our study was designed to determine whether prenalterol produced improvement in exercise tolerance in patients with severe resistant heart failure. This assessment was used as an objective way of determining quality of life. The results show a definite trend towards improvement. The fact that evidence of improvement in left ventricular performance was lacking does not detract from the results.
Two placebo controlled studies have recently reported that prenalterol was of little benefit.3435 Why are our findings different? In both of these studies several of the patients had cardiomyopathy with normal coronary arteries or left ventricular failure of unknown origin, and some of the patients were in NYHA class IV. In contrast, all our patients had left ventricular failure of ischaemic origin and class IV patients were specifically excluded so that we studied a more homogenous group of patients. Additionally, the greater number of patients in our study may have enabled us to observe changes not apparent in the small groups of Lambertz (n= 16)34 and Currie (n= 6). 35 The dose of prenalterol used in the Lambertz study34 was lower than that which we used with resulting serum concentrations approximately half of those we obtained. In Currie's study35 the treatment period was short so that it would have missed the clinical benefits which became apparent in our study after three months' treatment.
In conclusion, we found that prenalterol was well tolerated and no serious unwanted effects were observed. It appeared to be tolerated well in patients with angina as well as dyspnoea. The 
